April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Neutralization of Angiopoietin-2 Inhibits Ocular Angiogenesis and Vascular Leak, and Promotes Regression of Choroidal Neovascularization
Author Affiliations & Notes
  • Jingtai Cao
    Ophthalmology,
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • Yang Liu
    Ophthalmology,
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • Natasha Tirko
    Ophthalmology,
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • Weihong Xiao
    Ophthalmology,
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • Nicholas Papadopoulos
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • John S. Rudge
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • Christopher Daly
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • George D. Yancopoulos
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • Stanley J. Wiegand
    Ophthalmology,
    Regeneron Pharmaceuticals Inc, Tarrytown, New York
  • Footnotes
    Commercial Relationships  Jingtai Cao, Regeneron Pharmaceuticals Inc (E); Yang Liu, Regeneron Pharmaceuticals Inc (E); Natasha Tirko, Regeneron Pharmaceuticals Inc (E); Weihong Xiao, Regeneron Pharmaceuticals Inc (E); Nicholas Papadopoulos, Regeneron Pharmaceuticals Inc (E); John S. Rudge, Regeneron Pharmaceuticals Inc (E); Christopher Daly, Regeneron Pharmaceuticals Inc (E); George D. Yancopoulos, Regeneron Pharmaceuticals Inc (E); Stanley J. Wiegand, Regeneron Pharmaceuticals Inc (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 1799. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jingtai Cao, Yang Liu, Natasha Tirko, Weihong Xiao, Nicholas Papadopoulos, John S. Rudge, Christopher Daly, George D. Yancopoulos, Stanley J. Wiegand; Neutralization of Angiopoietin-2 Inhibits Ocular Angiogenesis and Vascular Leak, and Promotes Regression of Choroidal Neovascularization. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1799.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the role of angiopoietin-2 (Ang2) in corneal angiogenesis, vascular leak and inflammation following injury, and the effects of pharmacological neutralization of Ang2 on established choroidal neovascularization (CNV) in mice.

Methods: : Corneal angiogenesis was induced by intrastromal placement of nylon sutures in C57Bl/6 mice. A fully human Ang2 antibody, that also binds and neutralizes murine Ang2, (25mg/kg) or the Fc portion of human IgG (hFc, 10mg/kg) was injected subcutaneously (SC) on days 0, 3 and 6 following injury. Corneal vasculature was labeled by intravenous injection of FITC-conjugated lectin on day 9 after injury, and the extent of NV was evaluated in corneal flatmounts. Lymphatic vessels were co-localized in the same specimens by LYVE-1 immunostaining. Macrophage infiltration was evaluated in cross-sections stained with rat anti-mouse F4/80 monoclonal antibody. For choroidal angiogenesis, CNV was induced by subretinal injection of a 75% matrigel solution (0.5 µl) in adult 129S1/SvlmJ mice. By 34 days after injection, choroidal neovessels were present in the matrigel and subretinal space. Anti-Ang2 (25mg/kg, SC) or hFc (10mg/kg, SC) was injected on days 34, 37 and 40. The vasculature was labeled by perfusion of a DiI solution on day 42. CNV volume was quantified in serial cryo-sections.

Results: : Corneal NV, vascular leakage, and growth of lymphatic vessels into the injured cornea were significantly decreased by anti-Ang2 treatment, compared to controls treated with hFc. In the CNV study, choroidal neovessels were present in the matrigel deposit and subretinal space in all untreated animals 34 days after injection of matrigel. On day 42, CNV volume in hFc treated controls was 72.5% greater than the day 34 CNV baseline, while treatment with anti-Ang2 resulted in a decrease of 36.3% in CNV volume (p <0.05). Anti-Ang2 treatment also significantly reduced CNV vessel density by 63.3% from the baseline (p <0.05).

Conclusions: : Ang2 plays an important role in promoting the development of neovascularization, lymphangiogenesis and vascular leakage following corneal injury. Pharmacological inhibition of Ang2 not only blocked further development of CNV stimulated by subretinal deposition of matrigel, but also promoted the regression of recently formed CNV.

Keywords: neovascularization • growth factors/growth factor receptors • pathology: experimental 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×